TRIPLE NEGATIVE BREAST CANCER
Clinical trials for TRIPLE NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to reboot immune attack on tough breast cancer
Disease control Not yet recruitingThis study tests whether a three-drug combination (cromolyn, TQB2102, and panpulimab) can shrink tumors in people with advanced triple-negative breast cancer that no longer responds to immunotherapy. About 46 women aged 18 to 70 will receive the treatment. The goal is to see if t…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 03:21 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells modified to attack tumors that have a specific marker (GPNMB). It is for people with advanced alveolar soft part sarcoma, renal cell carcinoma, or triple-negative breast cancer that…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 26, 2026 03:20 UTC
-
Could a local anesthetic stop triple-negative breast cancer recurrence?
Disease control Not yet recruitingThis study tests whether injecting the numbing drug levobupivacaine around the tumor and nearby nerves during breast-conserving surgery can help prevent triple-negative breast cancer from returning. About 760 women who have already had chemotherapy and are eligible for lumpectomy…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Institut Jean-Godinot • Aim: Disease control
Last updated May 26, 2026 03:20 UTC
-
Could a different chemo drug improve outcomes for black caribbean women with aggressive breast cancer?
Disease control Not yet recruitingThis study compares two chemotherapy drugs—gemcitabine and paclitaxel—in 750 Black Caribbean women with metastatic triple-negative breast cancer who have not yet had treatment for their advanced disease. The goal is to see if gemcitabine, typically used later, works better as a f…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: AntiCancer Research Jamaica • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New drug shows promise for Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study tests a new drug called ARX788 in 36 adults with HER2-low breast cancer that has spread or cannot be removed by surgery. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells. The goal is to see if it shrinks tumors and how long the effect…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
Breast cancer breakthrough: Surgery-Free option on the horizon?
Disease control Not yet recruitingThis study looks at whether women with triple-negative breast cancer who have a complete response to chemo-immunotherapy can safely avoid breast and lymph node surgery. About 150 participants will be randomly assigned to either standard treatment with surgery or the same treatmen…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: NA • Sponsor: Institut Curie • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New hope for High-Risk breast cancer: immunotherapy after standard care
Disease control Not yet recruitingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard post-surgery treatment can help prevent breast cancer from coming back in people with early-stage triple-negative breast cancer who still have cancer after initial chemo and immunotherapy. Ab…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
New personalized vaccine trial aims to supercharge immune attack on aggressive breast cancer
Disease control Not yet recruitingThis early-phase trial tests a personalized cancer immunotherapy (PCI) designed to train the immune system to attack a patient's unique tumor. It is given alongside standard chemotherapy and immunotherapy for newly diagnosed triple negative breast cancer that has not spread. Some…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
Freeze and fight: new combo tackles tough breast cancer
Disease control Not yet recruitingThis study tests a new approach for women with early-stage triple negative breast cancer, a high-risk type. The treatment combines cryoablation (freezing the tumor) with immunotherapy drugs to help the immune system better recognize and attack cancer cells. The goal is to see if …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Texas Tech University Health Sciences Center • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New cancer drug ITC-6146RO enters first human tests
Disease control Not yet recruitingThis early-phase trial tests a new drug called ITC-6146RO in about 100 adults with advanced or metastatic cancers (prostate, lung, breast, or other solid tumors) that have stopped responding to standard therapies. The study has two parts: first, finding a safe dose, then checking…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: IntoCell, Inc • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New dosing guidelines aim to prevent fever and treatment delays in cancer patients with rare blood trait
Disease control Not yet recruitingThis study looks at whether using special dosing guidelines for people with the Duffy null blood trait can help them avoid treatment delays and dangerous fevers during chemotherapy for multiple myeloma or triple-negative breast cancer. About 90 participants will be enrolled, and …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Andrew Hantel, MD • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo therapy targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study tests a new oral drug, BLEX 404, combined with chemotherapy (docetaxel) in people with advanced triple negative breast cancer. The goal is to find a safe dose and see if the combination helps shrink tumors. About 44 women aged 20-70 will take part.
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: BioLite, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New combo aims to boost breast cancer remission before surgery
Disease control Not yet recruitingThis phase 3 trial tests a personalized approach for people with stage II or III triple-negative breast cancer. Participants first receive 12 weeks of standard chemo plus immunotherapy. Those with a good response continue the same treatment; those with a poor response are switche…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
Could breast cancer treatment skip surgery? new trial explores non-surgical path
Disease control Not yet recruitingThis study tests whether some people with early-stage breast cancer can safely avoid surgery after chemotherapy and radiation. Participants will be monitored with MRIs, mammograms, and blood tests to check if the cancer stays away. The goal is to see if a non-surgical approach wo…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
AI could help doctors choose the best treatment for aggressive breast cancer
Knowledge-focused Not yet recruitingThis study will test an AI tool that looks at tumor samples to help doctors decide the best treatment for people with triple-negative breast cancer (TNBC). About 50 adults with early-stage TNBC who are scheduled for chemotherapy before surgery will take part. The goal is to see i…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated May 26, 2026 03:17 UTC
-
Blood test may spot hidden cancer months before scans
Knowledge-focused Not yet recruitingThis study tests whether a blood test that looks for cancer DNA can find returning triple-negative breast cancer earlier than standard check-ups. Thirty people who finished treatment for stage II or III TNBC will be randomly assigned to usual follow-up or usual follow-up plus reg…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Knowledge-focused
Last updated May 26, 2026 03:17 UTC